Recent Tweets Page 37

Leiman #worldcdx Data commons: majority is cfDNA, also lists cfRNA, exosomes etc. Pre-analytical WG: leaders from Novartis, Illumina, MSKCC.

11:53am September 12th 2019 via Twitter Web App

Leiman #worldcdx Started 3 clinical trials (breast, prostate, lung), reimb working group. Data commons est'd, SOP w/curation, processing

11:48am September 12th 2019 via Twitter Web App

Leiman #worldcdx Shows slide of member list, https://t.co/ejxE4XCCUQ Originally part of the Cancer Moonshot. Met w/FDA Aug '16

11:46am September 12th 2019 via Twitter Web App

Leiman #worldcdx Meet 4x/year, 35 members, recognizes data sharing / evidence generation as fundamental req'ments

11:45am September 12th 2019 via Twitter Web App

Q: Physician limitations on using an LDT? Weiss #worldcdx They can choose - FDA doesn't regulate medicine

9:20am September 12th 2019 via Twitter Web App

Q: Thoughts on plasma? Weiss #worldcdx They are trying to catch up. Consensus groups: rec'd situations where tissue unavailable

9:19am September 12th 2019 via Twitter Web App

Weiss #worldcdx Particularly reluctant for currently monitored pts. Not practical to offer two tests during transition.

9:15am September 12th 2019 via Twitter Web App

Weiss #worldcdx BRC-ABL: CDx avail in Dec '17, a superior test. But clinicians don't want to switch; greater restrictions on spec handling

9:15am September 12th 2019 via Twitter Web App

Weiss #worldcdx PIK3CA: 2 LDTs offered, Sanger, NGS; RGQ PCR approved in May '19. Exclusive uptake for CDx due to sponsored testing

9:11am September 12th 2019 via Twitter Web App

Weiss #worldcdx Reimbursement: payors don't care whether it is a CDx or LDT: antibody test for Her2. Codes lag-time is shorter now.

9:10am September 12th 2019 via Twitter Web App

Weiss #worldcdx CDx designed at the time of clinical trials; time to approval may be long, LDTs can be modified but CDx can't

9:04am September 12th 2019 via Twitter Web App

Weiss #worldcdx PD-L1 cutoffs: the lab is challenged with spec Ab, spec protocol, spec machine to preserve cutoffs.

9:01am September 12th 2019 via Twitter Web App

Weiss #worldcdx When precision in cutoffs req'd, CDx preferred; is a specialized control tissue req'd, available? NTRK so rare.

9:00am September 12th 2019 via Twitter Web App

Weiss #worldcdx CDx complexity: multi-analyte difficult, 'black box' algorithms virtually impossible to replicate.

8:59am September 12th 2019 via Twitter Web App

Weiss #worldcdx MMR/MSI for I-O: no approved CDx, along with NTRK fusions. CLIA-approved LDT is sufficient.

8:57am September 12th 2019 via Twitter Web App

Weiss #worldcdx Is it a CDx or LDT? FDA has 37 CDx. They offer 8, with a variety of technologies.

8:50am September 12th 2019 via Twitter Web App

Lawrence Weiss (NeoGenomics) #worldcdx Companion Diagnostics and Precision Medicine - role of NeoGenomics

8:48am September 12th 2019 via Twitter Web App

Stuart Martin (U Maryland) #worldcdx Accelerating functional analysis of patient tumor cells to reduce metastasis

8:22am September 12th 2019 via Twitter Web App

Sireci #worldcdx Meet customers where they are; RNA hyb capture (ILMN), and now partnering with TMO as hyb capture doesn't 'maximize access'

8:18am September 12th 2019 via Twitter Web App

Destenaves #worldcdx In practice after approval: Pt, physician value; assay avail & reimburseemnt; clin guidelines

5:31pm September 11th 2019 via Twitter Web App

Destenaves #worldcdx Key steps of CDx: scientific understanding, Dx platform availability and utility, and regulatory acceptance

5:30pm September 11th 2019 via Twitter Web App

Destenaves #worldcdx Shows 250K genomes analyzed (on teh way to 2M), 90% of clinical pipeline is PM; $230M invested in Dx partnerships

5:23pm September 11th 2019 via Twitter Web App

Benoit Destenaves (AstraZeneca) #worldcdx Key Considerations for Accelerating the Integration of Diagnostic Testing

5:22pm September 11th 2019 via Twitter Web App

Shaw #worldcdx But pts are generally not retested. Resistance is tested via LBx.

4:44pm September 11th 2019 via Twitter Web App

Q: What types of computational considerations? Shaw #worldcdx For the KB - can be rerun at any time. But manual curation of lit is req'd

4:44pm September 11th 2019 via Twitter Web App

Shaw #worldcdx May need to look at treating cancer earlier with PM - not in late-stage disease. 'We need to treat it as if we know it'

4:42pm September 11th 2019 via Twitter Web App

Shaw #worldcdx Looking at co-mutations in lung cancer - ID Rx vulnerabilities. Skoulidis Cancer Disc 2015 https://t.co/vU25fFHefH

4:41pm September 11th 2019 via Twitter Web App

Shaw #worldcdx N.B. @kennamshaw is speaking with such clarity - awesome talk!

4:40pm September 11th 2019 via Twitter Web App

Shaw #worldcdx Pt not eligable early, become eligable later but early report used. 40 new biomarkers in 18 mos.

4:35pm September 11th 2019 via Twitter Web App

Shaw #worldcdx No standard rules - shows same patient, two different reports, two different rec's. But need to evolve decision support

4:34pm September 11th 2019 via Twitter Web App

Shaw #worldcdx Came up with literature, aggregate data, annotate fn significance. "One person's VUS is another person's enrollment criteria"

4:33pm September 11th 2019 via Twitter Web App

Shaw #worldcdx Of the reminder: 124/354 refused second line. Now 230 came back for 2L: but only 69% had test results mentioned.

4:30pm September 11th 2019 via Twitter Web App

Shaw #worldcdx 17% of the pts never came back. Got tested, sought Rx, and pt never knew they had an actionable result, never were contacted.

4:29pm September 11th 2019 via Twitter Web App

Shaw #worldcdx Whether 50 genes, 500 genes, or WES: only 125 actionable genes to work with. MD Andersen - why is this so hard?

4:25pm September 11th 2019 via Twitter Web App